MicroPort CardioFlow Wins Shareholder Approval for Share Consolidation Effective 24 February

MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) has provided an announcement.

Shareholders of MicroPort CardioFlow Medtech Corporation have overwhelmingly approved a share consolidation at an extraordinary general meeting held on 11 February 2026, with 100% of votes cast in favor and all directors attending either in person or electronically. The consolidation, which reduces the number of issued shares from about 6.37 billion to roughly 1.27 billion, will take effect on 24 February 2026, potentially improving the stock’s trading efficiency and price perception while existing blue share certificates remain valid as documents of title but no longer for trading once new light-gold certificates are issued.

The company confirmed that dealings in the consolidated shares will commence at 9:00 a.m. on 24 February 2026, subject to no further share issuance or buybacks before that date. Adjustments will also be made to share options in line with the new capital structure, and arrangements for free exchange of share certificates and odd-lot matching are expected to smooth the transition for investors and help maintain orderly trading in the consolidated stock.

The most recent analyst rating on (HK:2160) stock is a Sell with a HK$0.74 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.

More about MicroPort CardioFlow Medtech Corp.

MicroPort CardioFlow Medtech Corporation is a Hong Kong-listed medical technology company focused on cardiovascular interventions. The group develops and markets minimally invasive products such as transcatheter valve and structural heart therapies, targeting hospitals and cardiac centers in China and international markets.

Average Trading Volume: 6,719,515

Technical Sentiment Signal: Sell

Current Market Cap: HK$4.9B

For an in-depth examination of 2160 stock, go to TipRanks’ Overview page.